Fadia A Kamal1, Deanne M Mickelsen2, Katherine M Wegman1, Joshua G Travers1, Jacob Moalem3, Stephen R Hammes4, Alan V Smrcka5, Burns C Blaxall6. 1. The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 2. Aab Cardiovascular Research Institute, Department of Medicine, University of Rochester Medical Center, Rochester, New York. 3. Department of Surgery, University of Rochester Medical Center, Rochester, New York; Department of Medicine, University of Rochester Medical Center, Rochester, New York. 4. Department of Medicine, University of Rochester Medical Center, Rochester, New York. 5. Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, New York. 6. The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. Electronic address: burns.blaxall@cchmc.org.
Abstract
OBJECTIVES: The authors propose simultaneous inhibition of Gβγ signaling in the heart and the adrenal gland as a novel therapeutic approach for heart failure (HF). BACKGROUND: Elevated sympathetic nervous system activity is a salient characteristic of HF progression. It causes pathologic desensitization of β-adrenergic receptors (β-AR), facilitated predominantly through Gβγ-mediated signaling. The adrenal glands are key contributors to the chronically elevated plasma catecholamine levels observed in HF, where adrenal α2-AR feedback inhibitory function is impaired also through Gβγ-mediated signaling. METHODS: We investigated the efficacy of a small molecule Gβγ inhibitor, gallein, in a clinically relevant, pressure-overload model of HF. RESULTS: Daily gallein treatment (10 mg/kg/day), initiated 4 weeks after transverse aortic constriction, improved survival and cardiac function and attenuated cardiac remodeling. Mechanistically, gallein restored β-AR membrane density in cardiomyocytes, attenuated Gβγ-mediated G-protein-coupled receptor kinase 2-phosphoinositide 3-kinase γ membrane recruitment, and reduced Akt (protein kinase B) and glycogen synthase kinase 3β phosphorylation. Gallein also reduced circulating plasma catecholamine levels and catecholamine production in isolated mouse adrenal glands by restoring adrenal α2-AR feedback inhibition. In human adrenal endocrine tumors (pheochromocytoma), gallein attenuated catecholamine secretion, as well as G-protein-coupled receptor kinase 2 expression and membrane translocation. CONCLUSIONS: These data suggest small molecule Gβγ inhibition as a systemic pharmacologic therapy for HF by simultaneously normalizing pathologic adrenergic/Gβγ signaling in both the heart and the adrenal gland. Our data also suggest important endocrine/cardiovascular interactions and a possible role for small molecule Gβγ inhibition in treating endocrine tumors such as pheochromocytoma, in addition to HF.
OBJECTIVES: The authors propose simultaneous inhibition of Gβγ signaling in the heart and the adrenal gland as a novel therapeutic approach for heart failure (HF). BACKGROUND: Elevated sympathetic nervous system activity is a salient characteristic of HF progression. It causes pathologic desensitization of β-adrenergic receptors (β-AR), facilitated predominantly through Gβγ-mediated signaling. The adrenal glands are key contributors to the chronically elevated plasma catecholamine levels observed in HF, where adrenal α2-AR feedback inhibitory function is impaired also through Gβγ-mediated signaling. METHODS: We investigated the efficacy of a small molecule Gβγ inhibitor, gallein, in a clinically relevant, pressure-overload model of HF. RESULTS: Daily gallein treatment (10 mg/kg/day), initiated 4 weeks after transverse aortic constriction, improved survival and cardiac function and attenuated cardiac remodeling. Mechanistically, gallein restored β-AR membrane density in cardiomyocytes, attenuated Gβγ-mediated G-protein-coupled receptor kinase 2-phosphoinositide 3-kinase γ membrane recruitment, and reduced Akt (protein kinase B) and glycogen synthase kinase 3β phosphorylation. Gallein also reduced circulating plasma catecholamine levels and catecholamine production in isolated mouse adrenal glands by restoring adrenal α2-AR feedback inhibition. In humanadrenal endocrine tumors (pheochromocytoma), gallein attenuated catecholamine secretion, as well as G-protein-coupled receptor kinase 2 expression and membrane translocation. CONCLUSIONS: These data suggest small molecule Gβγ inhibition as a systemic pharmacologic therapy for HF by simultaneously normalizing pathologic adrenergic/Gβγ signaling in both the heart and the adrenal gland. Our data also suggest important endocrine/cardiovascular interactions and a possible role for small molecule Gβγ inhibition in treating endocrine tumors such as pheochromocytoma, in addition to HF.
Authors: Tabetha M Bonacci; Jennifer L Mathews; Chujun Yuan; David M Lehmann; Sundeep Malik; Dianqing Wu; Jose L Font; Jean M Bidlack; Alan V Smrcka Journal: Science Date: 2006-04-21 Impact factor: 47.728
Authors: Alexander Neumeister; Dennis S Charney; Inna Belfer; Marilla Geraci; Courtney Holmes; Yehonatan Sharabi; Tanya Alim; Omer Bonne; David A Luckenbaugh; Husseini Manji; David Goldman; David S Goldstein Journal: Pharmacogenet Genomics Date: 2005-03 Impact factor: 2.089
Authors: Markus Velten; Georg D Duerr; Thilo Pessies; Julia Schild; Ralph Lohner; Jan Mersmann; Oliver Dewald; Kai Zacharowski; Sven Klaschik; Tobias Hilbert; Andreas Hoeft; Georg Baumgarten; Rainer Meyer; Olaf Boehm; Pascal Knuefermann Journal: Cardiovasc Res Date: 2012-09-12 Impact factor: 10.787
Authors: Cinzia Perrino; Sathyamangla V Naga Prasad; Mrinali Patel; Matthew J Wolf; Howard A Rockman Journal: J Am Coll Cardiol Date: 2005-06-07 Impact factor: 24.094
Authors: Anastasios Lymperopoulos; Giuseppe Rengo; Hajime Funakoshi; Andrea D Eckhart; Walter J Koch Journal: Nat Med Date: 2007-02-18 Impact factor: 53.440
Authors: Cinzia Perrino; Sathyamangla V Naga Prasad; Jacob N Schroder; Jonathan A Hata; Carmelo Milano; Howard A Rockman Journal: Circulation Date: 2005-05-16 Impact factor: 29.690
Authors: Sarah M White; Lauren M North; Emily Haines; Megan Goldberg; Lydia M Sullivan; Jeffrey D Pressly; David S Weber; Frank Park; Kevin R Regner Journal: Mol Pharmacol Date: 2014-07-15 Impact factor: 4.436
Authors: Joshua G Travers; Fadia A Kamal; Iñigo Valiente-Alandi; Michelle L Nieman; Michelle A Sargent; John N Lorenz; Jeffery D Molkentin; Burns C Blaxall Journal: J Am Coll Cardiol Date: 2017-08-22 Impact factor: 24.094
Authors: Joshua G Travers; Fadia A Kamal; Jeffrey Robbins; Katherine E Yutzey; Burns C Blaxall Journal: Circ Res Date: 2016-03-18 Impact factor: 17.367
Authors: Javier Rangel-Moreno; Jesi Y To; Teresa Owen; Bruce I Goldman; Alan V Smrcka; Jennifer H Anolik Journal: Arthritis Rheumatol Date: 2016-09 Impact factor: 10.995